

Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: Haemostasis, platelet activation and antithrombotic therapy

Moroi, Alyssa J.; Watson, Steve P.

DOI:

[10.1016/j.bcp.2015.02.004](https://doi.org/10.1016/j.bcp.2015.02.004)

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Moroi, AJ & Watson, SP 2015, 'Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: Haemostasis, platelet activation and antithrombotic therapy', *Biochemical Pharmacology*, vol. 94, no. 3, pp. 186-194. <https://doi.org/10.1016/j.bcp.2015.02.004>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

NOTICE: this is the author's version of a work that was accepted for publication. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Moroi AJ, Watson SP, Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: haemostasis, platelet activation and antithrombotic therapy, *Biochemical Pharmacology* (2015), <http://dx.doi.org/10.1016/j.bcp.2015.02.004>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Accepted Manuscript

Title: Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: Haemostasis, platelet activation and antithrombotic therapy

Author: Alyssa J. Moroi Steve P. Watson



PII: S0006-2952(15)00108-2
DOI: <http://dx.doi.org/doi:10.1016/j.bcp.2015.02.004>
Reference: BCP 12190

To appear in: *BCP*

Received date: 3-11-2014
Revised date: 9-2-2015
Accepted date: 9-2-2015

Please cite this article as: Moroi AJ, Watson SP, Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: haemostasis, platelet activation and antithrombotic therapy, *Biochemical Pharmacology* (2015), <http://dx.doi.org/10.1016/j.bcp.2015.02.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1
2
3
4
5
6
7
8
9 **Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM**
10 **receptors: haemostasis, platelet activation and antithrombotic therapy**
11
12
13

14 Authors: Alyssa J. Moroi and Steve P. Watson
15
16

17
18 Corresponding Author: Alyssa J. Moroi
19
20

21 Centre for Cardiovascular Sciences, Institute for Biomedical Research, The College of
22
23 Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United
24
25 Kingdom
26
27

28
29 E-mail: Alyssa Moroi <A.J.Moroi@bham.ac.uk>
30
31

32
33 TEL: +44 (0) 121 414 2560
34
35
36
37
38

39 **ABSTRACT**
40
41

42 Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that are activated in
43
44 response to various stimulants, and they regulate many processes including inflammation;
45
46 the stress response; gene transcription; and cell proliferation, differentiation, and death.
47
48

49 Increasing reports have shown that the PI3Ks and their downstream effector Akt are
50
51 activated by several platelet receptors that regulate platelet activation and haemostasis.
52
53

54 Platelets express two immunoreceptor tyrosine based activation motif (ITAM) receptors,
55
56 collagen receptor glycoprotein VI (GPVI) and Fc γ receptor IIA (Fc γ RIIA), which are
57
58 characterized by two YxxL sequences separated by 6–12 amino acids. Activation of an
59
60
61
62
63
64
65

1
2
3
4
5
6
7 ITAM receptor initiates a reaction cascade via its YxxL sequence in which signaling
8
9 molecules such as spleen tyrosine kinase (Syk), linker for activation of T cells (LAT) and
10
11 phospholipase C γ 2 (PLC γ 2) become activated, leading to platelet activation. Platelets also
12
13 express another receptor, C-type lectin 2 (CLEC-2), which has a single YxxL sequence, so
14
15 it is appropriately called a hemITAM receptor. ITAM receptors and the hemITAM receptor
16
17 share many signaling features. Here we will summarize our current knowledge about how
18
19 the PI3K/Akt pathway regulates (hem)ITAM receptor-mediated platelet activation and
20
21 haemostasis and discuss the possible benefits of targeting PI3K/Akt as an antithrombotic
22
23 therapy.
24
25
26
27
28
29
30

31 **Abbreviation**

32
33 PI3K, phosphoinositide 3-kinases; ITAM, immunoreceptor tyrosine based activation motif;
34
35 GPVI, glycoprotein VI; Fc γ RIIA, Fc γ receptor IIA; Syk, spleen tyrosine kinase; LAT,
36
37 linker for activation of T cells; PLC γ 2, phospholipase C gamma 2; CLEC-2, C-type lectin;
38
39 vWF, von Willebrand factor; TxA₂, thromboxane A₂; GPCR, G protein-coupled receptor;
40
41 TCR, T cell receptor; Lck, leukocyte-specific kinase; Zap-70, zeta-chain-associated protein
42
43 kinase 70; CRP, collagen-related peptides; HEV, high endothelial venule; Grb2, growth
44
45 factor receptor-bound protein-2; Gads, growth factor receptor-bound protein-2 adaptor
46
47 downstream of Shc; PTEN, phosphatase and tensin homologue deleted on chromosome 10;
48
49 DAG, diacyl glycerol; SHIP, SH2 domain-containing inositol polyphosphatase; PKC,
50
51 protein kinase C; CaMKK, Ca²⁺/calmodulin-dependent protein kinase kinase; SNP, single-
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 nucleotide polymorphism; GSK3, glycogen synthase kinase 3; LiCl, lithium chloride; MEK,
8
9 MAPK/ERK kinase; ERK, extracellular signal-regulated kinase

10 11 12 13 14 **Keywords**

15
16 Protein kinase B; Phosphatidylinositol 3-kinases; Platelets; C-type lectin; Glycoprotein VI

17 18 19 20 21 **1. Introduction**

22
23 Platelets are released from megakaryocytes in the bone marrow and have a short life,
24
25 circulating in blood for about 9–10 days. Because they are fragments of megakaryocytes,
26
27 they have no nucleus. Platelet activation is a vital step in both haemostasis: a physiological
28
29 response that prevents significant blood loss following vascular injury and thrombosis: a
30
31 pathological extension of normal haemostasis [1]. Platelets circulate in healthy vessels, but
32
33 when a vessel wall is damaged, platelets become activated when they interact with the
34
35 newly exposed subendothelial collagen. Platelets are tethered onto the site of injury through
36
37 interaction of the glycoprotein (GP) Ib-V-IX complex with von Willebrand factor (vWF),
38
39 which is bound to exposed collagen. This interaction enables collagen to interact with
40
41 glycoprotein (GP) VI, thus initiating signaling events that lead to the conformational
42
43 change (activation) of integrins α IIb β 3 and α 2 β 1, enabling the former to bind to vWF and
44
45 fibrinogen and the latter to bind to collagen. Following activation of these receptors,
46
47 secondary mediators such as ADP and thromboxane A₂ (TxA₂) are secreted from platelets
48
49 and activate ADP receptors and TxA₂ receptors, further supporting the haemostatic and
50
51 thrombotic function of platelets. Dysregulation or dysfunction of platelet signaling events
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 can lead to bleeding disorders or formation of arterial thrombosis; thus it is important to
8
9 understand platelet signaling pathways so we can treat these disorders appropriately [1].
10
11 PI3K and its downstream effectors are activated by several platelet receptors, however
12
13 inhibition of PI3K isoforms or their downstream effectors leads to only partial blockade of
14
15 platelet activation and only has a significant effect in response to low agonist
16
17 concentrations [1-3]. This characteristic therefore makes them very attractive targets for
18
19 novel antithrombotic therapy reducing the risk of potential bleeding side effects, which
20
21 current strategies have to negotiate.
22
23
24
25
26
27

28 **2. Platelet receptors**

29
30 Platelets are known to express a wide variety of receptors: G protein-coupled receptors
31
32 (GPCRs) (thrombin receptors PAR-1 and PAR-4), integrins (α IIb β 3, α 2 β 1, α 5 β 1, α 6 β 1,
33
34 α v β 3), leucine-rich repeat (LRR) family receptors (GPIb/IX/V), ADP receptors (P2Y₁ and
35
36 P2Y₁₂), TxA₂ receptors (TP α and TP β), immunoglobulin superfamily receptors (GPVI,
37
38 Fc γ RIIA), and C-type lectin-like receptors (P-selectin and CLEC-2) [4] (Table1). Many of
39
40 these receptors have had their signaling mechanisms investigated with data suggesting they
41
42 share a high degree of similarity with the receptors activated under growth factors or
43
44 hormones in nucleated cells. The common signaling pathways are activation of
45
46 phospholipase C (PLC) and elevation of intracellular Ca²⁺, leading to secretion of
47
48 secondary mediators to facilitate platelet activation and conversion of inactive integrin via a
49
50 conformational change to its ligand-binding active state (inside-out signaling). Among
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 these signaling events, phosphoinositide signaling is active in platelets and has been shown
8
9 to play a critical role in platelet activation [1].
10

11 12 **3. Platelet ITAM receptors** 13

14
15 The immunoreceptor tyrosine based activation motif (ITAM) is a highly conserved
16
17 sequence defined by $Y_{xx}(L/I)_{x_{6-12}}Y_{xx}(L/I)$ which can be found in the cytosolic domain in a
18
19 number of receptors and adaptor proteins. When phosphorylated, ITAMs serve as docking
20
21 sites for SH2 domain containing tyrosine kinases which are critical for initiation of
22
23 signaling cascades. GPVI is the major collagen receptor on platelets. Through association
24
25 with the Fc receptor γ (FcR γ) chain, which contains two YxxL motifs, signal transduction is
26
27 initiated demonstrating that the GPVI-FcR γ complex is essential for GPVI signaling [5].
28
29
30

31
32 Other ITAM receptors of C-type lectin-like receptor (CLR) family such as dendritic cell-
33
34 associated C-type lectin-2 (Dectin-2) which is predominantly expressed in myeloid cells is
35
36 also known to interact with FcR γ and signal through the YxxL sequences in FcR γ .
37
38

39
40 GPVI/FcR γ is the only ITAM receptor expressed in mouse platelets, but human platelets
41
42 express both GPVI/FcR γ and Fc γ RIIA both of which signal through a tandem YxxL
43
44 sequences. Platelet ITAM receptors utilize the same family of signaling proteins as ITAM
45
46 receptors in other hematopoietic cells such as T cell receptor (TCR) and B cell receptor
47
48 (BCR). GPVI uses predominantly Lyn and Syk and the PLC γ 2 isoform, whereas the TCR
49
50 uses leukocyte-specific kinase (Lck) and zeta-chain-associated protein kinase 70 (Zap-70)
51
52 and the PLC γ 1 isoform. Because of these similarities, it is possible to study the signaling
53
54 pathways of the platelet ITAM receptors by transfecting platelet signaling proteins into T
55
56 and B cell lines.
57
58
59
60
61
62
63
64
65

3.1. GPVI

GPVI is a platelet-specific collagen receptor that is expressed on the platelet surface.

Genetic deletion of GPVI in mice abolished the platelet response to collagen but the mice only exhibited a mild defect in haemostasis [6, 7]. Similarly, patients with a GPVI defect only show mild bleeding disorders [8, 9]. GPVI has two extracellular Ig domains, a mucin-rich stalk and short cytoplasmic domain. The cytosolic tail of GPVI has a sequence for binding to calmodulin and one that binds to the SH3 domain of Src family kinases such as Fyn and Lyn. It is non-covalently associated with the FcR γ -chain homodimer, which contains an ITAM. Both GPVI and FcR γ are essential for collagen-induced platelet activation [5]. Once phosphorylated on two conserved tyrosines after GPVI engagement by collagen, the FcR γ chain is responsible for signal transduction. Phosphorylation of FcR γ chain leads to binding of the tyrosine kinase Syk, inducing downstream signaling cascades, which are similar to those of other immune receptors as described above[10]. FcR γ is also used by other ITAM receptors in the C-type lectin-like receptors such as Dectin-2 and MINCLE. In these cases, activation of Syk, PLC δ , CARD9-Bcl10-Malt-1 and MAPK pathways induce cytokine production in myeloid cells which is important for host defence [11]. However, these cell surface receptors including Dectin-2 are not expressed in platelets and thus the role of CARD9-Bcl10-Malt-1 pathway downstream of GPVI and C-type lectin-like receptor stimulation in platelets is unknown.

Collagen is a powerful activator of platelets that activate both GPVI and integrin α 2 β 1. A number of GPVI-specific ligands have been used to delineate the signaling pathways, including collagen-related peptide (CRP), which contains GPVI recognition motif GPO

1
2
3
4
5
6
7 (glycine-proline-hydroxyproline); GPVI-specific antibodies; and the snake venom toxin
8
9 convulxin [12].
10

11 12 13 14 **3.2. Fcγ Receptor IIA (FcγRIIA)**

15
16 FcγRIIA is the second ITAM receptor in human platelets. Unlike GPVI, FcγRIIA has its
17
18 ITAM within its cytoplasmic tail. Since mouse platelets lack a gene equivalent to FcγRIIA,
19
20 transgenic mice expressing human FcγRIIA have been generated. Mouse platelets
21
22 expressing human FcγRIIA have enhanced spreading on fibrinogen and thrombus
23
24 formation in vivo, and it has been proposed that this is due to enhanced integrin outside-in
25
26 signaling [13]. FcγRIIA signals through the same pathways as GPVI; therefore, in this
27
28 commentary we will focus on the signaling through GPVI as an ITAM receptor.
29
30
31
32
33
34

35 **4. Platelet hemITAM receptors**

36
37 The C-type lectin-like receptor CLEC-2 (encoded by the *Clec1b* gene), and the closely
38
39 related receptor, Dectin-1 which is found on dendritic cells, are founder members of a novel
40
41 class of signaling receptors defined by a single YxxL sequence and known as a hemITAM
42
43 (ITAM-like) receptor. CLEC-2 is the only hemITAM receptor in platelets.
44
45
46
47
48
49

50 **4.1. CLEC-2**

51
52 CLEC-2 is a C-type lectin-like receptor that is highly expressed in platelets and to a lesser
53
54 extent, in other cell types such as activated dendritic cells and B cells [14]. The first ligand
55
56 to be identified for CLEC-2 was rhodocytin, which was purified from the Malayan pit viper,
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 *Calloselama rhodostoma*, by the groups of Huang [15] and Morita [16] in the 1990s. To
8
9 date, the only endogenous ligand found for CLEC-2 is podoplanin. Podoplanin is a
10
11 sialomucin-like glycoprotein expressed in a variety of cells but is absent from vascular
12
13 endothelial cells and is ordinarily not expressed in the vasculature.
14
15

16
17 In vitro studies have shown that treating platelets with CLEC-2 agonists activate platelets,
18
19 inducing aggregation and secretion, identifying CLEC-2 as a platelet activating receptor
20
21 [17]. We and others have previously shown using murine models that homozygous loss of
22
23 CLEC-2 results in developmental defects in brain vasculature, lung inflation and
24
25 lymphatics, and is associated with perinatal lethality [18, 19]. However, the role of CLEC-2
26
27 in haemostasis and thrombus formation seems to be limited; CLEC-2-deficient mice show
28
29 no or minimal elongation of tail bleeding times which is also seen in GPVI-deficient mice
30
31 [19, 20]. These data indicate that mechanisms independent of CLEC-2 and GPVI mediate
32
33 platelet activation or that platelet activation by other agonists such as thrombin and ADP
34
35 are sufficient to form haemostatic clots in the tail.
36
37
38
39
40
41

42 More recently, Herzog et al. showed that platelet CLEC-2 is important for maintaining high
43
44 endothelial venule (HEV) barrier function during chronic inflammation [21]. Through
45
46 interaction with podoplanin expressing-fibroblastic reticular cells, CLEC-2 dependent
47
48 pathways were required to prevent vascular leak in HEV in reactive lymph nodes.
49
50

51 Moreover, CLEC-2 has been reported to be involved in capturing HIV-1 virus particles and
52
53 transferring of HIV-1 infection by platelets together with other receptors [22]. This is the
54
55 only report implicating CLEC-2 in pathogen recognition. It would be interesting to
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 speculate whether CLEC-2 plays a more general role in pathogen recognition since the
8
9 structurally related receptor Dectin-1 is a known pattern recognition receptor (PRR). This
10
11 family of proteins serve as protection against fungi recognising conserved microbial
12
13 structures known as pathogen associated molecular patterns (PAMPs) leading to the
14
15 activation of transcription factor nuclear factor-kappa B (NF- κ B). Taken together these
16
17 reports suggest CLEC-2 has a number of roles which are not related to haemostasis.
18
19
20
21

22 **5. Comparison of ITAM and hemITAM receptors in platelets**

23
24
25 From the studies detecting signaling events and proteomic analysis it has been revealed that
26
27 the CLEC-2 shares many of its signaling cascades with GPVI and signals through
28
29 activation of Syk, Src and PLC γ 2 using adaptor proteins such as LAT and SH2-containing
30
31 leukocyte protein of 76kDa (SLP-76) [23]. Moreover, in vivo experiments on GPVI/CLEC-
32
33 2-double knockout mice indicated that loss of both receptors resulted in severe defects in
34
35 haemostasis and arterial thrombus formation, whereas deletion of GPVI or CLEC-2 alone
36
37 only resulted in a minor or negligible defect in haemostasis and thrombus stability. This
38
39 suggests that there is considerable redundancy in the function of these two receptors in
40
41 these events [24].
42
43
44
45
46
47

48 Common signaling pathways in ITAM and hemITAM receptors in platelets are illustrated
49
50 in Fig. 1. Upon ITAM and hemITAM receptor stimulation, the tyrosine residue in the YxxL
51
52 motifs in both receptors becomes phosphorylated enabling Syk to bind through its two SH2
53
54 domains and undergo both autophosphorylation and further phosphorylation by Src family
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 kinases [25]. These events occur after a delay of 10 seconds upwards after receptor
8
9 stimulation.

10
11
12 The next step in the signaling cascade is recruitment and phosphorylation of LAT by
13
14 activated Syk. Phosphorylated LAT then serves as a platform that binds growth factor
15
16 receptor-bound protein-2 (Grb2), growth factor receptor-bound protein-2 adaptor
17
18 downstream of Shc (Gads) and PLC γ 2. Adaptor protein SLP-76 is recruited to LAT by
19
20 binding to Gads or Grb2 which are critical for full activation of PLC γ 2. PI3K is also
21
22 recruited to LAT and generates phosphatidylinositol (3,4,5)-triphosphate (PIP3) from
23
24 phosphatidylinositol (4, 5)-bisphosphate (PIP2). Adaptor proteins Vav1 and 3 have also
25
26 been shown to be recruited to the LAT signalosome by binding to SLP-76 and Syk to
27
28 mediate PLC γ 2 activation. The binding of PLC γ 2 to phosphorylated LAT and PIP3 on the
29
30 plasma membrane further stabilizes its localization to LAT. In addition, PIP3 recruits the
31
32 tyrosine kinases Btk and Tec which phosphorylate PLC γ 2 leading to its activation.
33
34
35 Activated PLC γ 2 generates secondary messengers, inositol-1,4,5-triphosphate (IP3) and
36
37 1,2-diacylglycerol (DAG), which release Ca²⁺ from the intracellular store and activate
38
39 protein kinase C (PKC), respectively. These pathways lead to a common platelet activation
40
41 cascade, resulting in platelet aggregation and dense granule secretion, which release the
42
43 positive feedback mediator ADP and TxA₂ formation. In addition, activation of PKC also
44
45 leads to activation of Raf-1/MEK/ERK pathways; however, unlike Raf-1 pathway
46
47 activation in Dectin-1, it is not clear if this leads to NF- κ B activation.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 Syk signaling can also activate NF- κ B via CARD9/Bcl10/MALT1 downstream of other
8
9 hemITAMs, such as Dectin-1, in myeloid cells. Although MALT1 and Bcl10 are expressed
10
11 in platelets, it is currently unclear if following (hem)ITAM receptor activation this
12
13 signaling pathway plays a direct role in platelet activation [26].
14
15

16
17 Although there are similarities between GPVI and CLEC-2 signaling, there are also
18
19 quantitative and qualitative differences between these pathways (Fig. 2). First, GPVI uses
20
21 the YxxL sequences in the associated FcR γ chain, whereas CLEC-2 uses YxxL sequence in
22
23 its own cytoplasmic domain. Secondly, as described above, ITAM receptors use two YxxLs,
24
25 whereas the hemITAM receptor CLEC-2 only has a single YxxL sequence motif. As a
26
27 consequence, in ITAM receptors Syk binds to two YxxLs in a single receptor, whereas in
28
29 hemITAM receptors, Syk binds to two phosphorylated receptors bridging them via its
30
31 tandem SH2 domains [27]. Thirdly, there are differences in proximal signaling events;
32
33 Suzuki-Inoue et al. have reported that platelets from mice deficient in SLP-76, which is an
34
35 adaptor protein that binds to LAT, do not respond to GPVI agonists. This is consistent with
36
37 the role of SLP-76 in other hematopoietic cells, including T cells where SLP-76 deficiency
38
39 leads to a failure in T cell development [17, 28]. However, in CLEC-2 signaling, although
40
41 platelets from SLP-76-deficient mice do not respond to a low concentration of CLEC-2
42
43 agonist, this can be overcome by adding a high concentration [17]. Similar results were
44
45 observed for platelets from Vav1/Vav3 double-deficient mice; they fail to respond to high
46
47 concentration of GPVI-specific agonist, but although unresponsive to CLEC-2 agonist at
48
49 low concentration, they respond normally to high concentration [17]. Taken together these
50
51 results demonstrate that SLP-76 and Vav1/Vav3 are essential for GPVI signaling whereas
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 the requirement of these adaptor proteins are overcome at high agonist concentrations in
8
9 CLEC-2 signaling. Moreover, these data may suggest that CLEC-2 may use other, as yet
10
11 unknown, adaptor proteins for signaling. A fourth difference is in the role of secondary
12
13 mediators used to reinforce platelet activation following GPVI or CLEC-2 activation.
14
15 Pollitt et al. reported that blocking secondary mediators such as ADP and TxA₂ can block
16
17 platelet activation at a low concentration of GPVI agonists but this is overcome at higher
18
19 concentrations. In contrast, under the same conditions, platelet activation through CLEC-2
20
21 signaling is severely inhibited, including activation of Syk and downstream signaling
22
23 events. This was insurmountable using high concentrations of agonists in human platelets
24
25 [29] but not in mouse platelets [30]. However, the exact mechanism of how these secondary
26
27 mediators reinforce CLEC-2 signaling is unknown and ADP or TxA₂ stimulation itself does
28
29 not activate CLEC-2. Also, in this paper, they reported that blocking actin polymerization
30
31 by cytochalasin D had no effect on maximum aggregation in GPVI-mediated platelet
32
33 activation but CLEC-2-mediated platelet activation is inhibited. These data suggest that
34
35 actin polymerization plays a key role in CLEC-2 signaling possibly by retaining CLEC-2
36
37 signaling molecules near CLEC-2 [29]. Although it is reported in T cells that actin
38
39 polymerization is important for immunological synapse formation, the role of actin
40
41 polymerization on CLEC-2-mediated adhesion to other cells has not yet been identified.
42
43
44
45
46
47
48
49
50 These observations demonstrate that although ITAM and hemITAM signaling in platelets
51
52 share many signaling features, the regulation and importance of a number of signaling
53
54 molecules downstream of Syk differ between these receptors.
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 To date there have not been any reports describing Syk-independent signaling events that
8
9 occur during GPVI and CLEC-2-mediated platelet activation. This is in contrast to the
10
11 hemITAM receptor Dectin-1 where Raf-1 can activate NF- κ B independent of Syk in
12
13 myeloid cells. Indeed, it has been reported that disruption of Syk activity completely blocks
14
15 platelet aggregation and secretion in response to GPVI or CLEC-2 agonists [31]. However,
16
17 it is noteworthy that Syk deficiency does not affect haemostasis whereas the GPVI/CLEC-2
18
19 double knockout mouse has a severe defect in haemostasis suggesting that a Syk
20
21 independent pathway may exist or that this is the consequence of loss of adhesion [24, 32].
22
23
24
25
26
27

28 **6. PI3K and Akt**

29
30 The PI3K/Akt pathway is activated in response to various types of stimulation including
31
32 growth factors, cytokines, integrin, hormones and extracellular matrix (ECM) proteins; and
33
34 this pathway regulates a wide spectrum of cellular processes including cell cycle
35
36 progression and cell survival. This is illustrated by the correlation of gain of function
37
38 mutations in PI3K or Akt resulting in cancer development. Furthermore, inhibitory
39
40 mutations on the phosphatase PTEN (phosphatase and tensin homologue deleted on
41
42 chromosome 10), which is a negative regulator for PI3K/Akt, are also found in cancer.
43
44
45
46
47

48
49 PI3Ks are family of lipid kinases that in platelets are reported to be activated and regulate
50
51 platelet activation [33]. PI3Ks catalyze the conversion of plasma membrane lipid PIP2 to
52
53 PIP3. There are three families of PI3K: class I, II and III. Class I PI3Ks phosphorylate PIP2
54
55 to generate PIP3. They are heterodimeric proteins consisting of a catalytic subunit (p110 α ,
56
57 p110 β , p110 δ and p110 γ) and a regulatory subunit. According to their catalytic subunit,
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 class I PI3Ks are further divided into class IA that is composed of p110 α , p110 β and p110 δ ,
8
9 each associating with a SH2-containing regulatory subunit (p50, p55 or p85) that binds to
10
11 phosphorylated tyrosine residues in a Y(P)xxM motif. Class IB consists of one catalytic
12
13 subunit p110 γ associated with a regulatory subunit (p101 and p84), which is regulated by
14
15 binding to G protein $\beta\gamma$ subunits following GPCR activation. Human and mouse platelets
16
17 express all class I PI3Ks but express p110 δ at low level [34, 35]. Class II PI3Ks produce
18
19 phosphatidylinositol (3) phosphate (PI3P) from phosphatidylinositol (PI) and also
20
21 contribute to phosphatidylinositol (3,4) biphosphate (PI(3,4)P₂) production. Three
22
23 monomers have been identified: ubiquitous PI3K-C2 α and C2 β and the liver specific PI3K-
24
25 C2 γ . Finally, in class III, the only member is vascular protein sortin 34 (Vps34) that is a PI
26
27 specific kinase that only generates PI3P and is ubiquitously expressed. The role of class I
28
29 PI3Ks have been studied in platelets, however the role of class II and III PI3Ks are not
30
31 known. Platelets also express PIP3 phosphatases that are known to regulate the level of
32
33 PIP3 by converting PIP3 back to PIP₂; PTEN, SH2 domain-containing inositol
34
35 polyphosphatase 1 (SHIP1), and SHIP2 [33].

36
37
38 One of the major downstream effectors from PI3K is the serine/threonine kinase Akt (also
39
40 known as protein kinase B). Mouse and human platelets express all three isoforms of Akt,
41
42 namely Akt1, Akt2 and Akt3 [2, 36-39]. The activation of Akt is mainly mediated by PI3K,
43
44 generating PIP3 that recruits Akt and the other PH domain-containing proteins to the
45
46 plasma membrane, keeping Akt in proximity to its upstream kinases. The activity of Akt is
47
48 regulated through phosphorylation of two residues, Thr308 and Ser473. Phosphorylation of
49
50 Thr308 is mediated by phosphoinositide-dependent kinase 1 (PDK1), and phosphorylation
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 of Ser473 is mediated by mTORC2 [40-43]. Consistent with this, platelets from PDK1-
8
9 deficient mice have impaired platelet activation and Akt phosphorylation only at Thr308
10
11 and have impaired thrombin-mediated platelet activation [42]. However, the importance of
12
13 phosphorylation at Ser473 is unknown in platelets since an mTORC2 inhibitor had no
14
15 effect on thrombin-mediated platelet activation [43]. In contrast, in other ITAM receptors
16
17 such as TCR, T cells from mTORC2 deficient mouse has significant reduction in
18
19 phosphorylation at Ser473 after stimulation and this leads to reduction in the Th2 cell
20
21 response such as IL-4 production suggesting that Ser473 phosphorylation is indispensable
22
23 for Akt activity [44].
24
25
26
27
28
29
30

31 **7.1. PI3K in platelet activation**

32
33 Studies on the role of PI3K in platelets have used genetically modified mice lacking PI3K
34
35 subsets and pharmacological approaches employing specific inhibitors for PI3Ks. Most of
36
37 the studies investigating the role of PI3K in platelets have used two structurally distinct
38
39 inhibitors, wortmannin and LY294002 that both inhibit class I and class II PI3Ks. From
40
41 these studies, it has been reported that PI3Ks are expressed in platelets and play an
42
43 important role in platelet activation in many processes by affecting Ca^{2+} mobilization,
44
45 aggregation and platelet spreading in response to several agonists such as collagen, CRP or
46
47 convulxin [45, 46], ristocetin/vWF [47], thrombin [36] and ADP [48]. However, the role of
48
49 each PI3K isoform differs depending on the agonist.
50
51
52
53
54
55

56 During GPVI signaling, it has been appreciated that PI3Ks are activated in two ways:
57
58 directly by GPVI signaling and indirectly via the production of secondary mediators and
59
60
61
62
63
64
65

1
2
3
4
5
6
7 subsequent activation of the ADP and TxA₂ receptors. In the presence of secondary
8
9 mediator inhibitors to block indirect activation of PI3Ks, and the PI3K inhibitors
10 wortmannin or LY294002, Akt phosphorylation, IP₃ accumulation, Ca²⁺ elevation, P-
11 selectin expression and thrombus formation of human platelets were all suppressed
12 demonstrating that direct activation of PI3K/Akt by GPVI signaling is important for
13
14 platelet activation [46]. As discussed in Section 5, CLEC-2 signaling is highly dependent
15
16 on secondary mediators. Therefore inhibition of platelet activation secondary mediators
17
18 leads to an almost complete loss of CLEC-2 activation making it difficult to ascertain
19
20 whether direct or indirect signaling is important for PI3K activation during CLEC-2
21
22 signaling.
23
24
25
26
27
28
29
30

31
32 The catalytic subunit for PI3K α , p110 α , is frequently mutated in various types of cancer,
33
34 however its role in platelets is not well known. Using a PI3K α specific inhibitor, PIK-75, it
35
36 has been demonstrated that blocking PI3K α partially inhibited Akt phosphorylation after
37
38 GPVI stimulation [46, 49]. Moreover, it has been reported that both PI3K α and PI3K β have
39
40 a non-redundant function under GPVI stimulation, with both isoforms being required for
41
42 full activation of PLC γ 2, IP₃ formation, Ca²⁺ elevation, thrombus formation and Rap1
43
44 activation, supporting distinct roles for both isoforms during platelet activation [46].
45
46
47
48
49

50 PI3K β is reported to be the major PI3K isoform regulating platelet activity downstream of
51
52 several platelet receptors including GPCRs, such as P2Y₁₂, and integrins through regulation
53
54 of PLC activation and Ca²⁺ elevation. Consistent with these reports, collagen-induced
55
56 aggregation, Ca²⁺ elevation, Rap1 activation and thrombus formation are impaired in mice
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 lacking the p85 α regulatory subunit (inhibiting class IA PI3Ks) [35] or p110 β catalytic
8
9 subunit of PI3K β [50]. This impairment of platelet activation was not regulated by the
10
11 function of PI3K as a scaffold protein since platelets from mice having the kinase dead
12
13 mutation of PI3K β also had impaired platelet activation [51]. Studies using PI3K β specific
14
15 inhibitors, TGX-221 and AZD6482, have also shown that it inhibits GPVI agonist-
16
17 mediated platelet activation including Ca²⁺ elevation [46].
18
19
20
21

22 Studies to investigate the role of PI3K γ in platelet function suggest activation of the kinase
23
24 is specific to ADP-induced platelet activation, with platelets from mice lacking p110 γ
25
26 catalytic subunit of PI3K γ demonstrating impaired aggregation to ADP, whereas the
27
28 response to other agonists including collagen were normal [52].
29
30
31
32

33 PI3K δ is highly enriched in leukocytes however expression in platelets is low compared to
34
35 other PI3K isoforms. It has been reported that mouse platelets lacking the catalytic subunit
36
37 of p110 δ had slightly reduced aggregation to submaximal concentrations of CRP but had a
38
39 normal response to GPCR agonists and spread normally on collagen [3]. This suggests that
40
41 PI3K δ plays a minor role in GPVI signaling, partially reducing aggregation only at low
42
43 agonist concentrations. This minor role in platelet activation is in contrast to its role in
44
45 BCR and TCR signaling where the p110 δ kinase dead mutant markedly impaired B cell and
46
47 T cell maturation [53]. These studies on each PI3K isoform show that there is a distinct
48
49 regulation of PI3K activation between different ITAM receptors in different hematopoietic
50
51 cell types. The importance of each PI3K isoform in CLEC-2 signaling has not yet been
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 analyzed but it is important to investigate whether there is different dependency to that on
8
9 GPVI.

10 11 12 13 **7.2. Akt in platelets**

14
15 As mentioned above, Akt is the main downstream effector for PI3K [7] and in most cases,
16
17 including GPVI signaling, the activation of Akt is amplified by secretion of ADP in
18
19 platelets [49, 54]. Additionally, PI3K-independent pathways of Akt regulation have been
20
21 reported. Akt is phosphorylated by PKC and by Ca²⁺/calmodulin-dependent protein kinase
22
23 kinase (CaMKK) in platelets; and in thrombin stimulation, early Akt phosphorylation was
24
25 poorly sensitive to PI3K inhibitors [36, 55]. In contrast to these reports, under GPVI
26
27 stimulation, treating platelets with wortmannin or LY294002 completely blocked the
28
29 phosphorylation of Akt with or without ADP, demonstrating that Akt activation is initiated
30
31 in a PI3K-dependent manner [49]. CLEC-2-mediated Akt activation is partially inhibited by
32
33 a PKC inhibitor, whereas wortmannin and LY294002 completely blocked phosphorylation.
34
35 This demonstrates that PI3K is the main upstream inducer for Akt activation in both GPVI
36
37 and CLEC-2 signaling, but that in CLEC-2 signaling, PKC also partially supports
38
39 activation of Akt by sustaining Akt phosphorylation at later timer point. It has also been
40
41 reported that PKC inhibition reduces Akt phosphorylation in GPVI-mediated activation
42
43 [49]. However, PKC inhibition also blocks ADP secretion therefore it is not clear if this is
44
45 due to inhibition of direct phosphorylation of Akt by PKC or indirect inhibition by loss of
46
47 ADP-dependent Akt phosphorylation.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 Studying the function of Akt in platelets is predominantly achieved by using mice models
8
9 with deletion of individual Akt isoforms. Among the genetically modified mice generated,
10
11 only Akt1 deficient mice demonstrated a significant defect in response to collagen.
12
13 Specifically, Akt1 deficiency reduced platelet aggregation and secretion after collagen
14
15 stimulation, with prolonged tail bleeding times suggesting deletion of Akt1 is sufficient to
16
17 impair haemostasis [2, 56]. In contrast, deletion of Akt2 resulted in a reduced platelet
18
19 response to thrombin or TxA2 but a normal respond to collagen [2, 39, 57]. An enhanced
20
21 defect was seen in mouse platelets lacking two Akt isoforms, accomplished by Akt2
22
23 knockdown in Akt1-deficient mice since the double knock-out is lethal [9, 10]. These data
24
25 indicate that Akt isoforms have both non-redundant and redundant roles in supporting
26
27 platelet activation. Of importance to this review, during collagen-mediated platelet
28
29 activation, Akt1 is the isoform preferentially activated and also contributes more directly to
30
31 haemostasis.
32
33
34
35
36
37
38

39 It has been reported that Akt3 deficient mice also respond normally to collagen stimulation,
40
41 while having a reduced response to thrombin and TxA2 [39]. However, the role of Akt3 in
42
43 platelet activation is controversial with Moore et al. reporting that although Akt3 is
44
45 expressed in platelets, they were unable to detect activation of Akt3 after agonist
46
47 stimulation [37].
48
49
50
51

52 Pharmacological inhibitors for each isoform have not yet been developed however the role
53
54 of Akt has also been studied using the pan Akt inhibitor MK2206. It has been shown to
55
56 significantly suppress human platelet activation under both GPVI and CLEC-2 stimulation
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 in human platelets [37]. However, for GPVI, the Akt inhibitor did not completely block
8
9 platelet aggregation even at a low agonist concentration. In contrast, during CLEC-2
10
11 signaling, the Akt inhibitor almost completely blocked the aggregation and secretion at low
12
13 concentrations of agonist. These differences of Akt dependency between GPVI and CLEC-
14
15 2 may be attributable to CLEC-2 being highly dependent on secondary mediator signaling
16
17 compared to GPVI, as discussed earlier.
18
19
20
21

22 For future investigations, it would be worthwhile to study the roles of the individual Akt
23
24 isoforms in human platelets because it has been reported that a single-nucleotide
25
26 polymorphism (SNP) in Akt2 is associated with reduced P-selectin expression after CRP
27
28 stimulation in platelets [58]. However, the fact that Akt isoforms have a common domain
29
30 organization and high sequence homology makes it a challenge to develop specific
31
32 inhibitors for each isoform. Taken together these results using Akt isoform deficient mice
33
34 or pharmacological inhibitors for Akt demonstrates a role of Akt in (hem)ITAM receptor
35
36 mediated platelet activation. However, the precise mechanism by which Akt supports
37
38 platelet activation remains poorly characterized and several candidates have been suggested
39
40 as Akt substrates which is discussed in Section 8.
41
42
43
44
45
46
47
48
49

50 **8. PI3K and Akt effectors in platelet activation**

51 In ITAM and hemITAM signaling, several candidates are proposed as an effector under the
52
53 PI3K/Akt pathway (Fig. 3). Akt is known to phosphorylate more than 100 substrates.
54
55 Glycogen synthase kinase 3 β (GSK3 β) is known to be one of the main substrates for Akt in
56
57 a wide range of cell types. GSK3 β is reported to be a negative regulator for platelet
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 activation, inhibitors potentiating platelet aggregation and secretion, and being developed
8
9 as a potential drug to treat diabetes, stroke, Alzheimer's and other diseases.
10
11 Phosphorylation of GSK3 at its N-terminal negative regulatory site (Ser21 and Ser9 in
12
13 GSK3 α and GSK3 β , respectively) inhibits GSK3 α/β activation [59]. Deficiency of Akt
14
15 isoforms has been reported to partially inhibit GSK3 β phosphorylation, suggesting that
16
17 each isoform has a redundant role in regulating GSK3 β . Several groups have reported that
18
19 GSK3 α/β inhibition potentiates platelet activation. The GSK3 α/β inhibitors LiCl and
20
21 SB216763 have been shown to potentiate thrombin-induced platelet activation but to inhibit
22
23 collagen-stimulated platelet activation, suggesting an opposite role for GSK3 α/β under
24
25 GPCR and ITAM receptors [39, 60, 61]. Moreover, using a new specific inhibitor for
26
27 GSK3 α/β , CHIR-99021, Moore et al. have shown that thrombin-mediated platelet
28
29 activation was potentiated in inhibitor-treated platelets. This was in contrast to CRP-
30
31 mediated platelet activation which was unaltered, further suggesting the differential
32
33 regulation of platelet activation by GSK3 α/β , resulting in a negative role in thrombin
34
35 receptor signaling but positive or negligible role in GPVI signaling in platelets [37]. These
36
37 discrepant results from the studies on GPVI signaling using GSK3 α/β inhibitors which
38
39 show a negative or no effect in GPVI-mediated platelet activation may be due to the
40
41 different specificity of these inhibitors since LiCl and SB216763 inhibit GSK3 α/β and
42
43 several other kinases at the concentrations used in these studies [62]. Alternatively,
44
45 collagen may regulate GSK3 α/β downstream of integrin $\alpha 2\beta 1$, which is not activated by
46
47 CRP. In CLEC-2 signaling, the role of GSK3 α/β appears to be inhibitory and GSK3 α/β
48
49 inhibitors potentiate platelet activation to rhodocytin.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 Another potential effector under PI3K activation is ERK (extracellular signal-regulated
8
9 kinase), one of the MAPKs (mitogen-activated protein kinases). A series of studies have
10
11 reported that, dependent on the conditions, activation of MAPK plays a minor role in
12
13 platelet activation by GPCRs and GPVI [63, 64]. Studies on the involvement of MAPK in
14
15 platelet function have been performed using pharmacological inhibitors. The MEK
16
17 (MAPK/ERK kinase) inhibitors U0126 and PD98059 that inhibit ERK activation have been
18
19 shown to inhibit platelet aggregation and secretion [64, 65]. On the other hand, Börsch-
20
21 Haubold et al. demonstrated that the MEK inhibitor PD98059 had no effect on platelet
22
23 aggregation induced by collagen [65]. This discrepancy could be explained by the
24
25 experimental conditions as the latter study was performed in the presence of a
26
27 cyclooxygenase inhibitor that blocks TxA₂ to counter the inhibitory effect of PD98059
28
29 against this class of enzyme. These results however do not rule out the possibility that ERK
30
31 may contribute to platelet activation by GPVI through the regulation of TxA₂ formation
32
33 (which is why ERK inhibitors had no effect under TxA₂ blockage). Wortmannin treatment
34
35 was shown to inhibit the ERK phosphorylation in collagen-stimulated platelets at a later
36
37 time point [66]. These observations suggest a role of PI3K in phosphorylating ERK at a
38
39 later time point which could sustain ERK activation and support platelet activation
40
41 following both GPVI and CLEC-2 stimulation.
42
43
44
45
46
47
48
49
50

51 In addition to activating Akt and ERK, PIP3 generation by PI3K can lead to the recruitment
52
53 of PLC γ 2, Btk and Tec, inducing PLC activation which is a key player in platelet activation
54
55 as described in Section 5 [67-69]. This inhibition of PLC activation by PI3K inhibition can
56
57 lead to impaired Ca²⁺ elevation, integrin inside-out signaling and PKC activation,
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 influencing more diverse pathways than just Akt or ERK activation. Consistent with this, it
8
9 has been reported that PI3K inhibitors inhibit PLC γ 2 activation as shown by impaired Ca²⁺
10
11 elevation in LY294002 or wortmannin treated platelets after GPVI stimulation
12
13 demonstrating PLC γ 2 is regulated by PI3K [45, 46].
14
15
16
17

18 **9. PI3K/Akt pathways in human diseases and drug development**

19
20
21 As mentioned above, Akt is the main downstream effector for PI3K and has been
22
23 demonstrated to play a role in platelet activation in (hem)ITAM receptors and haemostasis.
24
25 Consistent with these reports using mouse models, expression of a SNP in the Akt2
26
27 associated with human platelet response in a screening of 500 healthy European individuals
28
29 suggests a role of Akt in human thrombosis or bleeding disorders [58]. Moreover, in the
30
31 PI3K family, a SNP associated with PI3K γ expression was also found to associate with
32
33 changes in mean platelet volume and annexin V binding [70]. These observations further
34
35 suggest a role for the PI3K/Akt pathway in human bleeding disorders and cardiovascular
36
37 diseases. However, the functional redundancy of each isoform of PI3K or Akt could make
38
39 it rather unlikely that a defect in a single isoform would result in the development of a
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

In the regulation of ITAM and hemITAM receptors in platelets, patients lacking GPVI display only a mild bleeding tendency and mice with either a GPVI or CLEC-2 deficiency have only a mildly prolonged tail bleeding time and reduced thrombus stability. These minor effects of GPVI and CLEC-2 on general haemostasis make them a good therapeutic target for anti-thrombotics without bleeding side effects. To date, Akt seems to be a good

1
2
3
4
5
6
7 therapeutic target that is differentially involved in GPVI and CLEC-2 signaling, having a
8
9 partial effect on GPVI signaling and blocking CLEC-2 signaling. Moreover, molecules
10
11 involved in the PI3K/Akt pathway are known to be frequently mutated in cancer patients
12
13 [71], and cancer patients are at a high risk of developing venous thromboembolism, making
14
15 it essential to treat these patients with anti-thrombotic drugs. An Akt inhibitor may be ideal
16
17 for treating cancer patients since it has a relatively mild effect on GPVI- and CLEC-2-
18
19 mediated platelet activation in haemostasis and also can block development of the cancer.
20
21 In PI3K-regulating therapy, an inhibitor targeting PI3K β would seem to be ideal for this
22
23 purpose based on the data obtained from PI3K-deficient mice and inhibitors. However, the
24
25 PI3K β inhibitor TGX-221, which has been reported to reduce adhesion to fibrinogen and
26
27 to reduce thrombosis in a rat injury model, had no effect on haemostasis as assessed by tail
28
29 bleeding time in rats [72]. Moreover, as a treatment against cancers and tumors, the pan Akt
30
31 inhibitor MK2206 is now in a phase 2 trial; further, combination of this inhibitor with other
32
33 anticancer agents such as receptor tyrosine kinase inhibitors, has been found to augment the
34
35 efficiency of this antitumor therapy [73].
36
37
38
39
40
41
42
43

44 **Acknowledgements**

45
46
47 This work has been supported by the Wellcome Trust (grant no. 088410). We thank Dr. SM
48
49 Jung, University of Cambridge and Dr S Lax, University of Birmingham for reading and
50
51 commenting on this manuscript.
52
53
54
55

56 **Disclosure of Conflict of Interests**

57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 The authors state that they have no conflict of interest.
8
9

10 **References**

- 11
12 [1] Swieringa F, Kuijpers MJ, Heemskerk JW, van der Meijden PE. Targeting platelet
13 receptor function in thrombus formation: the risk of bleeding. *Blood Rev.* 2014;28:9-21.
14 [2] Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV. Impaired platelet responses
15 to thrombin and collagen in AKT-1-deficient mice. *Blood.* 2004;104:1703-10.
16 [3] Senis YA, Atkinson BT, Pearce AC, Wonerow P, Auger JM, Okkenhaug K, et al. Role
17 of the p110delta PI 3-kinase in integrin and ITAM receptor signalling in platelets. *Platelets.*
18 2005;16:191-202.
19 [4] Kauskot A, Hoylaerts MF. Platelet receptors. *Handb Exp Pharmacol.* 2012:23-57.
20 [5] Nieswandt B, Bergmeier W, Schulte V, Rackebrandt K, Gessner JE, Zirngibl H.
21 Expression and function of the mouse collagen receptor glycoprotein VI is strictly
22 dependent on its association with the FcRgamma chain. *J Biol Chem.* 2000;275:23998-
23 4002.
24 [6] Lockyer S, Okuyama K, Begum S, Le S, Sun B, Watanabe T, et al. GPVI-deficient
25 mice lack collagen responses and are protected against experimentally induced pulmonary
26 thromboembolism. *Thromb Res.* 2006;118:371-80.
27 [7] Bender M, Hagedorn I, Nieswandt B. Genetic and antibody-induced glycoprotein VI
28 deficiency equally protects mice from mechanically and FeCl(3) -induced thrombosis. *J*
29 *Thromb Haemost.* 2011;9:1423-6.
30 [8] Hermans C, Wittevrongel C, Thys C, Smethurst PA, Van Geet C, Freson K. A
31 compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder. *J*
32 *Thromb Haemost.* 2009;7:1356-63.
33 [9] Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in
34 glycoprotein VI that lack both collagen-induced aggregation and adhesion. *J Clin Invest.*
35 1989;84:1440-5.
36 [10] Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. *Thromb Res.*
37 2004;114:221-33.
38 [11] Kerscher B, Willment JA, Brown GD. The Dectin-2 family of C-type lectin-like
39 receptors: an update. *Int Immunol.* 2013;25:271-7.
40 [12] Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor?
41 *Blood.* 2003;102:449-61.
42 [13] Zhi H, Rauova L, Hayes V, Gao C, Boylan B, Newman DK, et al. Cooperative
43 integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo.
44 *Blood.* 2013;121:1858-67.
45 [14] Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, Franz B, Hess PR, et al.
46 Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type
47 lectin receptor CLEC-2. *Immunity.* 2012;37:276-89.
48 [15] Huang TF, Liu CZ, Yang SH. Aggretin, a novel platelet-aggregation inducer from
49 snake (*Calloselasma rhodostoma*) venom, activates phospholipase C by acting as a
50 glycoprotein Ia/IIa agonist. *Biochem J.* 1995;309 (Pt 3):1021-7.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7 [16] Shin Y, Morita T. Rhodocytin, a functional novel platelet agonist belonging to the
8 heterodimeric C-type lectin family, induces platelet aggregation independently of
9 glycoprotein Ib. *Biochem Biophys Res Commun.* 1998;245:741-5.
- 10 [17] Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, et al. A novel
11 Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.
12 *Blood.* 2006;107:542-9.
- 13 [18] Finney BA, Schweighoffer E, Navarro-Nunez L, Benezech C, Barone F, Hughes CE,
14 et al. CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development.
15 *Blood.* 2012;119:1747-56.
- 16 [19] Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura K, Eto K, et al. Essential
17 in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-
18 2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of
19 CLEC-2-deficient platelets. *J Biol Chem.* 2010;285:24494-507.
- 20 [20] Hughes CE, Navarro-Nunez L, Finney BA, Mourao-Sa D, Pollitt AY, Watson SP.
21 CLEC-2 is not required for platelet aggregation at arteriolar shear. *J Thromb Haemost.*
22 2010;8:2328-32.
- 23 [21] Herzog BH, Fu J, Wilson SJ, Hess PR, Sen A, McDaniel JM, et al. Podoplanin
24 maintains high endothelial venule integrity by interacting with platelet CLEC-2. *Nature.*
25 2013;502:105-9.
- 26 [22] Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, et al. DC-
27 SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. *J*
28 *Virology.* 2006;80:8951-60.
- 29 [23] Parguina AF, Alonso J, Rosa I, Velez P, Gonzalez-Lopez MJ, Guitian E, et al. A
30 detailed proteomic analysis of rhodocytin-activated platelets reveals novel clues on the
31 CLEC-2 signalosome: implications for CLEC-2 signaling regulation. *Blood.*
32 2012;120:e117-26.
- 33 [24] Bender M, May F, Lorenz V, Thielmann I, Hagedorn I, Finney BA, et al. Combined in
34 vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises
35 hemostasis and abrogates arterial thrombosis in mice. *Arterioscler Thromb Vasc Biol.*
36 2013;33:926-34.
- 37 [25] Spalton JC, Mori J, Pollitt AY, Hughes CE, Eble JA, Watson SP. The novel Syk
38 inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2
39 signaling in platelets. *J Thromb Haemost.* 2009;7:1192-9.
- 40 [26] Karim ZA, Zhang J, Banerjee M, Chicka MC, Al Hawas R, Hamilton TR, et al.
41 IkappaB kinase phosphorylation of SNAP-23 controls platelet secretion. *Blood.*
42 2013;121:4567-74.
- 43 [27] Hughes CE, Pollitt AY, Mori J, Eble JA, Tomlinson MG, Hartwig JH, et al. CLEC-2
44 activates Syk through dimerization. *Blood.* 2010;115:2947-55.
- 45 [28] Pivniouk V, Tsitsikov E, Swinton P, Rathbun G, Alt FW, Geha RS. Impaired viability
46 and profound block in thymocyte development in mice lacking the adaptor protein SLP-76.
47 *Cell.* 1998;94:229-38.
- 48 [29] Pollitt AY, Grygielska B, Leblond B, Desire L, Eble JA, Watson SP. Phosphorylation
49 of CLEC-2 is dependent on lipid rafts, actin polymerization, secondary mediators, and Rac.
50 *Blood.* 2010;115:2938-46.
- 51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7 [30] Borgognone A, Navarro-Nunez L, Correia JN, Pollitt AY, Thomas SG, Eble JA, et al.
8 CLEC-2-dependent activation of mouse platelets is weakly inhibited by cAMP but not by
9 cGMP. *J Thromb Haemost.* 2014;12:550-9.
- 10 [31] Hughes CE, Finney BA, Koentgen F, Lowe KL, Watson SP. The N-terminal SH2
11 domain of Syk is required for (hem)ITAM, but not integrin, signaling in mouse platelets.
12 *Blood.* 2015;125:144-54.
- 13 [32] Law DA, Nannizzi-Alaimo L, Ministri K, Hughes PE, Forsyth J, Turner M, et al.
14 Genetic and pharmacological analyses of Syk function in alphaIIb beta3 signaling in
15 platelets. *Blood.* 1999;93:2645-52.
- 16 [33] Jackson SP, Yap CL, Anderson KE. Phosphoinositide 3-kinases and the regulation of
17 platelet function. *Biochem Soc Trans.* 2004;32:387-92.
- 18 [34] Zhang J, Vanhaesebroeck B, Rittenhouse SE. Human platelets contain p110delta
19 phosphoinositide 3-kinase. *Biochem Biophys Res Commun.* 2002;296:178-81.
- 20 [35] Watanabe N, Nakajima H, Suzuki H, Oda A, Matsubara Y, Moroi M, et al. Functional
21 phenotype of phosphoinositide 3-kinase p85alpha-null platelets characterized by an
22 impaired response to GP VI stimulation. *Blood.* 2003;102:541-8.
- 23 [36] Kroner C, Eybrechts K, Akkerman JW. Dual regulation of platelet protein kinase B. *J*
24 *Biol Chem.* 2000;275:27790-8.
- 25 [37] Moore SF, van den Bosch MT, Hunter RW, Sakamoto K, Poole AW, Hers I. Dual
26 regulation of glycogen synthase kinase 3 (GSK3)alpha/beta by protein kinase C
27 (PKC)alpha and Akt promotes thrombin-mediated integrin alphaIIb beta3 activation and
28 granule secretion in platelets. *J Biol Chem.* 2013;288:3918-28.
- 29 [38] Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in
30 secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. *The*
31 *Journal of clinical investigation.* 2004;113:441-50.
- 32 [39] O'Brien KA, Stojanovic-Terpo A, Hay N, Du X. An important role for Akt3 in platelet
33 activation and thrombosis. *Blood.* 2011;118:4215-23.
- 34 [40] Dangelmaier C, Manne BK, Liverani E, Jin J, Bray P, Kunapuli SP. PDK1 selectively
35 phosphorylates Thr(308) on Akt and contributes to human platelet functional responses.
36 *Thrombosis and haemostasis.* 2014;111:508-17.
- 37 [41] Laurent PA, Severin S, Gratacap MP, Payrastre B. Class I PI 3-kinases signaling in
38 platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.
39 *Advances in biological regulation.* 2014;54:162-74.
- 40 [42] Chen X, Zhang Y, Wang Y, Li D, Zhang L, Wang K, et al. PDK1 regulates platelet
41 activation and arterial thrombosis. *Blood.* 2013;121:3718-26.
- 42 [43] Moore SF, Hunter RW, Hers I. mTORC2 protein complex-mediated Akt (Protein
43 Kinase B) Serine 473 Phosphorylation is not required for Akt1 activity in human platelets
44 [corrected]. *J Biol Chem.* 2011;286:24553-60.
- 45 [44] Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al.
46 The kinase mTOR regulates the differentiation of helper T cells through the selective
47 activation of signaling by mTORC1 and mTORC2. *Nat Immunol.* 2011;12:295-303.
- 48 [45] Pasquet JM, Bobe R, Gross B, Gratacap MP, Tomlinson MG, Payrastre B, et al. A
49 collagen-related peptide regulates phospholipase Cgamma2 via phosphatidylinositol 3-
50 kinase in human platelets. *Biochem J.* 1999;342 (Pt 1):171-7.
- 51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7 [46] Gilio K, Munnix IC, Mangin P, Cosemans JM, Feijge MA, van der Meijden PE, et al.
8 Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein
9 VI-induced platelet signaling and thrombus formation. *J Biol Chem.* 2009;284:33750-62.
10 [47] Yin H, Stojanovic A, Hay N, Du X. The role of Akt in the signaling pathway of the
11 glycoprotein Ib-IX induced platelet activation. *Blood.* 2008;111:658-65.
12 [48] Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, et al. Protease-activated
13 receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP
14 and cause human platelet aggregation independently of G(i) signaling. *Blood.*
15 2002;99:3629-36.
16 [49] Kim S, Mangin P, Dangelmaier C, Lillian R, Jackson SP, Daniel JL, et al. Role of
17 phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets. *J*
18 *Biol Chem.* 2009;284:33763-72.
19 [50] Gratacap MP, Guillermet-Guibert J, Martin V, Chicanne G, Tronchere H, Gaits-
20 Iacovoni F, et al. Regulation and roles of PI3Kbeta, a major actor in platelet signaling and
21 functions. *Adv Enzyme Regul.* 2011;51:106-16.
22 [51] Canobbio I, Stefanini L, Cipolla L, Ciralo E, Gruppi C, Balduini C, et al. Genetic
23 evidence for a predominant role of PI3Kbeta catalytic activity in ITAM- and integrin-
24 mediated signaling in platelets. *Blood.* 2009;114:2193-6.
25 [52] Hirsch E, Bosco O, Tropel P, Laffargue M, Calvez R, Altruda F, et al. Resistance to
26 thromboembolism in PI3Kgamma-deficient mice. *FASEB journal : official publication of*
27 *the Federation of American Societies for Experimental Biology.* 2001;15:2019-21.
28 [53] Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, et al. Impaired B
29 and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. *Science.*
30 2002;297:1031-4.
31 [54] Xiang B, Zhang G, Liu J, Morris AJ, Smyth SS, Gartner TK, et al. A G(i) -
32 independent mechanism mediating Akt phosphorylation in platelets. *J Thromb Haemost.*
33 2010;8:2032-41.
34 [55] Resendiz JC, Kroll MH, Lassila R. Protease-activated receptor-induced Akt activation-
35 -regulation and possible function. *Journal of thrombosis and haemostasis : JTH.*
36 2007;5:2484-93.
37 [56] Stojanovic A, Marjanovic JA, Brovkovich VM, Peng X, Hay N, Skidgel RA, et al. A
38 phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating
39 platelet secretion and aggregation. *J Biol Chem.* 2006;281:16333-9.
40 [57] Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in
41 secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. *J Clin*
42 *Invest.* 2004;113:441-50.
43 [58] Jones CI, Bray S, Garner SF, Stephens J, de Bono B, Angenent WG, et al. A
44 functional genomics approach reveals novel quantitative trait loci associated with platelet
45 signaling pathways. *Blood.* 2009;114:1405-16.
46 [59] Cohen P, Frame S. The renaissance of GSK3. *Nat Rev Mol Cell Biol.* 2001;2:769-76.
47 [60] Barry FA, Graham GJ, Fry MJ, Gibbins JM. Regulation of glycogen synthase kinase 3
48 in human platelets: a possible role in platelet function? *FEBS Lett.* 2003;553:173-8.
49 [61] Li D, August S, Woulfe DS. GSK3beta is a negative regulator of platelet function and
50 thrombosis. *Blood.* 2008;111:3522-30.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7 [62] Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity
8 of protein kinase inhibitors: a further update. *Biochem J.* 2007;408:297-315.
- 9 [63] Toth-Zsomboki E, Oury C, Cornelissen H, De Vos R, Vermynen J, Hoylaerts MF.
10 P2X1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by
11 enhancing myosin light chain kinase activation. *J Biol Chem.* 2003;278:46661-7.
- 12 [64] Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X. Two distinct roles of mitogen-
13 activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-
14 in retractile signaling pathway. *Blood.* 2009;113:893-901.
- 15 [65] Borsch-Haubold AG, Kramer RM, Watson SP. Inhibition of mitogen-activated protein
16 kinase kinase does not impair primary activation of human platelets. *Biochem J.* 1996;318
17 (Pt 1):207-12.
- 18 [66] Endale M, Lee WM, Kamruzzaman SM, Kim SD, Park JY, Park MH, et al.
19 Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired
20 glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation. *Br J*
21 *Pharmacol.* 2012;167:109-27.
- 22 [67] Rebecchi MJ, Pentyala SN. Structure, function, and control of phosphoinositide-
23 specific phospholipase C. *Physiol Rev.* 2000;80:1291-335.
- 24 [68] Fukuda M, Kojima T, Kabayama H, Mikoshiba K. Mutation of the pleckstrin
25 homology domain of Bruton's tyrosine kinase in immunodeficiency impaired inositol
26 1,3,4,5-tetrakisphosphate binding capacity. *J Biol Chem.* 1996;271:30303-6.
- 27 [69] Yang WC, Ching KA, Tsoukas CD, Berg LJ. Tec kinase signaling in T cells is
28 regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain. *J*
29 *Immunol.* 2001;166:387-95.
- 30 [70] Soranzo N, Rendon A, Gieger C, Jones CI, Watkins NA, Menzel S, et al. A novel
31 variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function.
32 *Blood.* 2009;113:3831-7.
- 33 [71] Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer.
34 *Oncogene.* 2005;24:7455-64.
- 35 [72] Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, et al.
36 PI 3-kinase p110beta: a new target for antithrombotic therapy. *Nat Med.* 2005;11:507-14.
- 37 [73] Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, et al. A phase 1
38 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and
39 trastuzumab in patients with HER2-positive solid tumors. *Breast Cancer Res.*
40 2013;15:R110.
- 41
42
43
44
45
46
47
48
49
50
51

52 **Figure Legends**

53
54
55 **Figure 1.** (hem)ITAM receptor signaling
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 Activation of ITAM receptor (GPVI) and hemITAM receptor (CLEC-2) induces the
8
9 recruitment and subsequent activation of Syk. Activated Syk induces activation of signaling
10
11 cascades that lead to the activation of PLC γ 2 and elevation of intracellular Ca²⁺ level for
12
13 which the adaptor protein LAT serves as a platform for this signaling cascade. This leads to
14
15 granule secretion, integrin activation and aggregation of platelets which reinforces platelet
16
17 activation.
18
19
20
21
22
23
24

25 **Figure 2.** Comparison of GPVI and CLEC-2 signaling

26
27
28 (i) ITAM receptor GPVI interacts with the covalent dimer of FcR- γ chain, in which each
29
30 monomer contains an ITAM sequence. Activation of GPVI receptor leads to a one-to-one
31
32 interaction of FcR- γ chain with Syk to activate Syk. The hemITAM receptor CLEC-2
33
34 requires two phosphorylated receptors to activate Syk. (ii) SLP-76 is essential for GPVI
35
36 signaling, whereas in CLEC-2 signaling, a high dose of agonist can overcome SLP-76
37
38 deficiency. (iii) Platelets from Vav1/Vav3 double knockout mice fail to respond to high
39
40 dose of GPVI agonist, whereas they respond to high dose of CLEC-2 agonist. (iv) Blocking
41
42 actin polymerization almost completely blocked CLEC-2-mediated platelet aggregation,
43
44 but it does not change the maximum aggregation in GPVI-mediated platelet aggregation.
45
46
47
48 (v) At high dose of agonist, secondary mediators are dispensable in GPVI signaling
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 **Figure 3.** Effectors under the PI3K/Akt pathway
8
9

10 Activation of ITAM receptor (GPVI) and hemITAM receptor (CLEC-2) induces activation
11 of PI3K which generates PIP3 in the plasma membrane. This induces the activation of Akt,
12 which then phosphorylates GSK3. Inhibition of GSK3 by Akt suppresses platelet activation
13 in GPVI signaling but potentiates activation in CLEC-2 signaling. PI3K also directly or
14 indirectly activates MEK and ERK, supporting platelet activation. PIP3 generation by PI3K
15 can also lead to activation of PLC γ 2 by recruiting PLC γ 2, Btk and Tec to the plasma
16 membrane to induce calcium elevation, PKC and platelet activation.
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Table 1** Overview of the receptors expressed in platelets
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Receptor	Ligand	Receptor type
PAR1 (only in human)	Thrombin, PAR1 peptide (synthetic)	G protein-coupled receptor
PAR4	Thrombin, PAR4 peptide (synthetic)	G protein-coupled receptor
P2Y ₁	ADP	G protein-coupled receptor
P2Y ₁₂	ADP	G protein-coupled receptor
TP	TxA ₂ , U46619 (synthetic)	G protein-coupled receptor
GPVI	Collagen, Laminin, CRP (synthetic), Convulxin (snake toxin), JAQ1 (antibody)	Ig
α 2 β 1	collagen	Integrin
α 6 β 1	Laminin	Integrin
GPIb-XI-V	vWF, Ristocetin (snake toxin)	Leucine-rich
α Ib β 3	Fibrinogen, vWF	Integrin
P2X ₁	ATP	Ca ²⁺ channel
CLEC-2	Podoplanin, Rhodocytin (snake toxin)	C type lectin-like




Figure 2





Figure 3






Figure 2 grayscale





Figure 3 grayscale



collagen, CRP, convulxin

podoplanin, rhodocytin

